[Industry Report] The Global State of Pharma Launch Excellence 2026/2027

Download your complimentary copy of the industry report today for an in-depth analysis of the trends, challenges and market forces shaping pharmaceutical launches. Explore the latest insights on market access, pricing and reimbursement, AI, launch execution, and evolving regulatory requirements, alongside real-world examples from leading pharmaceutical organisations.

• Why up to two-thirds of pharmaceutical launches fail to meet expectations and the common execution gaps separating launch readiness from launch success.
• How the first 6-12 months now determine long-term launch performance, with early access, adoption and payer decisions becoming increasingly difficult to reverse.
• The impact of the EU HTA Regulation and Joint Clinical Assessments, and what launch teams need to do now to prepare evidence strategies for a changing European market access landscape.
• How pricing, reimbursement and access pressures are reshaping launch strategy across Europe and the US, from Medicare negotiations to increasing payer scrutiny and value-based assessments.
• The rise of obesity, oncology and specialty therapies, with oncology spend forecast to exceed $440 billion globally by 2029 and obesity medicines projected to reach up to $280 billion by 2030.
• Practical AI use cases already improving launch performance, including forecasting, omnichannel optimisation, field enablement, medical insight generation and early signal detection.
• How leading organisations are evolving launch operating models, moving from milestone-based launch planning to continuous launch performance management.
• Real-world lessons from companies including AstraZeneca, Roche, Novartis, Teva and Sandoz on evidence generation, market access, launch sequencing and supply resilience